LGALS1 and hepatocellular carcinoma: To further determine the anti-tumor benefit of inhibiting the galectin-1 in combination with cisplatin, we used an in situ mouse hepatoma model generated by intrasplenic grafting of autologous hepatoma cells, ML-1 cells [26].